[ad_1]
President Kim Hee-Bio of Hong-Ryeol Kim, who is developing the next generation of cancer drugs Starvanip, is a joint investigation with the research team at Yonsei University School of Medicine for the first time in world. It was announced on the 4th with the Industry-University Cooperation Group of the Yonsei University School of Medicine.
“Based on the inorganic polyphosphate study, we found an important clue to the potential development of Corona 19 virus treatment without side effects in collaboration with the Yonsei University research team,” said Kim.
The discovery of the inhibition of the replication function of the corona19 virus host using this polymer is the result of a study carried out by Kim Hee-yeol, CEO of Heimbio, in collaboration with the research team of the Faculty of Medicine of the University from Yonsei.
Phosphate (polyphosphate) is a food and pharmaceutical additive that has been approved by the FDA and has already been shown to be safe.
President Kim said: “Recently, we have received a sample of infectious coronavirus disease (COVID-19) in Korea, and we have observed how Yonsei University observed how coronavirus polymers of different chain lengths act on the coronavirus at different concentrations. “We have discovered for the first time that coronavirus replication is inhibited in host cells to significant levels at different concentrations.”
Immediately after the discovery, the results were sent to Dr. Massimo Zolo of CEINGE, a biotechnology research center located in Naples, Italy. The virus collected from samples of the Italian Coronal Virus Infectious Disease (COVID-19) in Italy is currently used in Korean experiments using oropharyngeal cells. The same phosphorous polymer sample used was analyzed for comparison.
“Due to the simultaneous analysis of the genetic sequences of samples from promising subjects collected from various countries in Europe, including the prominent ones in Korea and Italy, we were able to see that the various sequences were altered. Based on this, in-depth research into varying viral replication capacity is currently underway with international researchers and international cooperation. Furthermore, Italian laboratories are conducting experiments to inhibit the replication of phosphorous polymers against real infections using confirmatory samples. “
‘Inpolymer’, which was discovered as a candidate for corona treatment19, has been studied constantly since the 1960s by Dr. Arthur Conberg, who won the Nobel Prize for Medicine in 1959. The study was started in 1997 by the team at German research, focusing on the results of a study that various chain-length phosphorous polymers have an inhibitory effect on the AIDS VIRUS (HIV-H1), another virus.
Phosphorous polymers are linear polymers of at least 3 to up to 1000 phosphates (PO43-) connected to each other, and are found in almost all living organisms such as bacteria, fungi, plants and mammals.
In particular, phosphorus is an important precursor that is the origin of life: it is an energy metabolite of all cells, a source of ATP supply, an energy source, storage of phosphate groups, binding with metal ions, regulators for stress and survival, and occurrence regulators. As a functioning inorganic compound, it is possible to develop a variety of new drugs through the use of genes that produce foreign substances and related genes.
“Polymer research began in 1993 while attending Stanford Medical School in the United States. “It was a study I started while taking a postdoctoral training course under the guidance of Dr. Arthur Conberg, Nobel Prize in Medicine Physiology.”
While studying molecular genetics at the University of Calton, Canada, Kim studied the ability to replicate plasmid DNA in dysentery. During postdoctoral studies at Stanford School of Medicine in the United States, in the field of DNA replication and polymerization, it was discovered to control the infarction of enzymes that produce foreign substances in soil bacteria that induce asthma and give fatal results to lung fibroblastoma. He is also the main character who created the biochemistry class at Kyunghee University College of Oriental Medicine.
“We complete the patent application as a pharmaceutical composition for the prevention and treatment of infectious diseases by coronavirus. The patent was 100% agreed with the co-inventors on the transfer to Heim Bio and will be announced in detail through an international magazine soon. We are also developing anti-cancer drugs for aerosol products that use in-cancer polymers and cancer of the refractory molecular subtype. In the future, we plan to continue research from various perspectives that require the development of coronavirus treatments and vaccines. “
Meanwhile, on 20, the research team of Professor Remy Charrell of the University of Ex Marseille, France, observed the corona19 virus on a pre-published platform (bioRxiv) after heating it from 60 140 to 140 ℃, and the results showed that “some viruses are heated for 1 hour. “It has still replicated the virus,” he said, and it is impacting the world.
It is good worldwide that a substance that can inhibit replication of the coronavirus has been discovered, as the severity of replication of the coronavirus, even at 60 degrees Celsius or higher, has emerged as a new problem. .
Heimbio is developing a star cancer drug, Starvanip (NYH817100), a candidate for the next-generation cancer drug that starves and kills only cancer cells. Currently, Phase 1 clinical trials are being conducted in the Department of Oncology, Severance Hospital, Yonsei University, for several cancer patients who do not achieve standard treatment in Korea.
